ARASENS: Darolutamide for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive pro... Author: ASCO2017 Added: 06/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts